期刊文献+

结直肠癌肝转移术前药物治疗进展 被引量:4

原文传递
导出
摘要 肝脏是结直肠癌转移最常见的靶器官,〉50%的结直肠癌病人会在其病程中出现肝脏转移,2/3的结直肠癌病人因为肝脏转移而死亡。手术仍是结直肠癌肝转移(colorectal cancer liver metastases,CRLM)病人获得治愈的惟一方法~[1],5年存活率〉50%,且有〉20%的病人存活〉10年。但是80%的CRLM病人初诊时为不可切除,且肝切除术后1年内复发率为30%~47%~[2-3]。
出处 《中国实用外科杂志》 CSCD 北大核心 2016年第4期447-450,共4页 Chinese Journal of Practical Surgery
基金 国家自然科学基金(No.81541143)
关键词 结直肠癌 肝转移 新辅助化疗 转化治疗 colorectal cancer liver metastases neoadjuvant chemotherapy conversion chemotherapy
  • 相关文献

参考文献2

二级参考文献20

  • 1Van Cutsem E,Peeters M,Siena S,et al.Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology . 2007
  • 2Elena De Mattia,Giuseppe Toffoli,Jerry Polesel,Mario D’Andrea,Giuseppe Corona,Vittorina Zagonel,Angela Buonadonna,Eva Dreussi,Erika Cecchin.Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment[J].Pharmacogenetics and Genomics.2013(10)
  • 3KimieSai,YoshiroSaito,NaokoTatewaki,MasakiyoHosokawa,NahokoKaniwa,TomokoNishimaki‐Mogami,MikihikoNaito,Jun‐ichiSawada,KuniakiShirao,TetsuyaHamaguchi,NoboruYamamoto,HideoKunitoh,TomohideTamura,YasuhideYamada,YuichiroOhe,TeruhikoYoshida,HironobuMinami,AtsushiOhtsu,YasuhiroMatsumura,NagahiroSaijo,HaruhiroOkuda.Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients[J]. British Journal of Clinical Pharmacology . 2010 (2)
  • 4Leonard B. Saltz,Stephen Clarke,Eduardo Díaz-Rubio,Werner Scheithauer,Arie Figer,Ralph Wong,Sheryl Koski,Mikhail Lichinitser,Tsai-Shen Yang,Fern,o Rivera,Felix Couture,Florin Sirzén,Jim Cassi.Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Japanese Journal of Clinical Oncology . 2008
  • 5Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian Lerchenmüller,Christoph Kahl,Gernot Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,J?rg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert H?ffkes,Markus Moehler,Reinhard U Lindig,Dominik P Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing.FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncology . 2014 (10)
  • 6Jie Li,Yu Wan,Shufang Na,Xiaochan Liu,Guicheng Dong,Zheqiong Yang,Jing Yang,Jiang Yue.Sex-dependent regulation of hepatic CYP3A by growth hormone: Roles of HNF6, C/EBPα, and RXRα[J]. Biochemical Pharmacology . 2014
  • 7Ken-ichi Fujita,Tomoko Sugiura,Hidenori Okumura,Saki Umeda,Noritaka Nakamichi,Yusuke Watanabe,Hiromichi Suzuki,Yu Sunakawa,Ken Shimada,Kaori Kawara,Yasutsuna Sasaki,Yukio Kato.Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans[J]. Pharmaceutical Research . 2014 (1)
  • 8Y Claire Wang,Klim McPherson,Tim Marsh,Steven L Gortmaker,Martin Brown.Health and economic burden of the projected obesity trends in the USA and the UK[J]. The Lancet . 2011 (9793)
  • 9Michael H. Court.Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system[J]. Drug Metabolism Reviews . 2010 (1)
  • 10Hiroshi Takane,Katsuyuki Kawamoto,Tomohiro Sasaki,Kuniaki Moriki,Kazuyo Moriki,Hiroya Kitano,Shun Higuchi,Kenji Otsubo,Ichiro Ieiri.Life-threatening toxicities in a patient with UGT1A1 * 6 /* 28 and SLCO1B1 * 15 /* 15 genotypes after irinotecan-based chemotherapy[J]. Cancer Chemotherapy and Pharmacology . 2009 (6)

共引文献123

同被引文献16

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部